secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001437749-24-008521
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired
----------------------------------------------------------------------------

- Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.
- R&D expenses $13.1M (up 68% YoY) due to in-use studies and DM199 manufacturing; G&A $8.2M (up 32%).
- ReMEDy2 Phase 2/3 trial: 6 U.S. sites open; interim enrollment of 144 patients expected by Q1 2025.
- Protocol modified to focus on moderate AIS (NIHSS 5-15) and exclude posterior strokes to boost efficacy.
- Appointed Dr. Lorianne Masuoka as CMO in Jan 2024 and Rebekah de Vitry Fries as VP Clinical Operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/0001437749-24-008521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/dmtp20240318_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-008521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer